Neoadjuvant therapy with doxorubicin-cyclophosphamide followed by weekly paclitaxel in early breast cancer: a retrospective analysis of 200 consecutive patients treated in a single center with a median follow-up of 9.5 years

被引：0
|
作者：
Lisi M. Dredze
Michael Friger
Samuel Ariad
Michael Koretz
Bertha Delgado
Ruthy Shaco-Levy
Margarita Tokar
Michael Bayme
Ravit Agassi
Maia Rosenthal
Victor Dyomin
Olga Belochitski
Shai Libson
Tamar Mizrahi
David B. Geffen
机构：
[1] Ben-Gurion University of the Negev,Faculty of Health Sciences
[2] Soroka University Medical Center,Department of Oncology
[3] Ben-Gurion University of the Negev,Department of Public Health
[4] Soroka Medical Center,Division of Surgery and The Eshkol Breast Center
[5] Soroka University Medical Center,Department of Pathology
[6] Soroka Medical Center,Department of Imaging and The Eshkol Breast Center
来源：
Breast Cancer Research and Treatment | 2022年 / 193卷
关键词：
Neoadjuvant; Doxorubicin-cyclophosphamide; Paclitaxel; Breast cancer; Real-world;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：597 / 612
页数：15
相关论文
共 45 条
  • [21] Retrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 months
    Ou Huang
    CanMing Chen
    JiaYi Wu
    ShuJie Chen
    XiaoSong Chen
    GuangYu Liu
    Zhen Hu
    JingSong Lu
    Jiong Wu
    ZhiMin Shao
    ZhenZhou Shen
    KunWei Shen
    BMC Cancer, 9
  • [22] Longer follow-up on cardiac safety and distant disease free survival of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab in patients with early-stage HER2-positive breast cancer.
    Wang, Rui
    Yu, Anthony Francis
    Steingart, Richard
    Patil, Sujata
    Baselga, Jose
    Norton, Larry
    Hudis, Cliff
    Dang, Chau T.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [23] Disease free survival rate with dose dense Doxorubicin and Cyclophosphamide followed by weekly Paclitaxel with Trastuzumab and Pertuzumab (ddACTHP) in patients with HER2-positive early stage breast cancer: A single institution experience
    Singh, Jasmeet C.
    Patil, Sujata
    Norton, Larry
    Robson, Mark
    Dang, Chau
    CANCER RESEARCH, 2020, 80 (04)
  • [24] Long-term follow-up of patients with metastatic breast cancer: results of a retrospective, single-center analysis from 2000 to 2005
    Geiger, Sandra
    Cnossen, Jitske Alida
    Horster, Sophia
    DiGioia, Dorit
    Heinemann, Volker
    Stemmler, Hans-Joachim
    ANTI-CANCER DRUGS, 2011, 22 (09) : 933 - 939
  • [25] Survival analysis of the prospectively randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy with weekly nab-paclitaxel with solvent-based paclitaxel followed by anthracycline/cyclophosphamide for patients with early breast cancer-GBG69
    Schneeweiss, Andreas
    Jackisch, Christian
    Schmatloch, Sabine
    Aktas, Bahriye
    Denkert, Carsten
    Schem, Christian
    Wiebringhaus, Hermann
    Kummel, Sherko
    Rhiem, Kerstin
    Warm, Mathias
    Fasching, Peter A.
    Just, Marianne
    Hanusch, Claus
    Hackmann, John
    Blohmer, Jens Uwe
    Gerber, Bernd
    Furlanetto, Jenny
    von Minckwitz, Gunter
    Nekljudova, Valentina
    Loibl, Sibylle
    Untch, Michael
    CANCER RESEARCH, 2018, 78 (04)
  • [26] Prognostic Factors in Patients with Stage II/III Breast Cancer Treated with Adjuvant Extension of Neoadjuvant Chemotherapy: A Retrospective Cohort Study with Ten-Years of Follow-Up Data
    Kim, Jeryong
    Lee, Jinsun
    Chang, Eilsung
    Suh, Kwangsun
    Lee, Cheoljoo
    Jee, Jongtae
    Shin, Hyungsub
    JOURNAL OF BREAST CANCER, 2011, 14 (01) : 39 - 45
  • [27] Subtype analysis from the GEICAM/2003-02 study: High-risk, node-negative breast cancer patients treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel
    Rojo, Federico
    Lluch, Ana
    Ruiz, Amparo
    Ruiz-Borrego, Manuel
    Barnadas, Agusti
    Calvo, Lourdes
    Gonzalez, Sonia
    Margeli, Mireia
    Rodriguez-Lescure, Alvaro
    Anton, Antonio
    Angel Segui, Miguel
    Munoz-Mateu, Montserrat
    Dorca, Joan
    Manuel Lopez-Vega, Jose
    Jara-Sanchez, Carlos
    Martin, Nuria
    Casas, Maribel
    Maria Carrasco, Eva
    Caballero, Rosalia
    Martin, Miguel
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [28] Troponin I and C-reactive protein as biomarkers for changes in left ventricular ejection fraction in patients with early stage breast cancer treated with dose-dense doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel with trastuzumab and lapatinib
    Morris, P. G.
    Chen, C.
    Lin, N.
    Moy, B.
    Come, S.
    Abbruzzi, A.
    Winer, E.
    Norton, L.
    Hudis, C. A.
    Dang, C. T.
    EJC SUPPLEMENTS, 2009, 7 (02): : 271 - 271
  • [29] Early invasive ductal breast cancer: Review after 5-year median follow-up of the first 681 patients treated by partial breast irradiation with intraoperative electron radiation therapy
    Philippson, C.
    Simon, S.
    Vandekerkhove, C.
    Veys, I.
    Noterman, D.
    De Neubourg, F.
    Roman, M.
    Nogaret, J. M.
    Larsimont, D.
    Desmet, A.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S84 - S84
  • [30] CA15-3 Adds Prognostic Information in "Luminal" Type Breast Cancer - A Single Center Experience Evaluating 700 Patients with a Median Follow-Up of 5 Years.
    Kantelhardt, E. J.
    Vetter, M.
    Steer, S.
    Ruider, T.
    Holzhausen, H-J
    Strauss, H-G
    Gross, R.
    Thomssen, C.
    CANCER RESEARCH, 2011, 71
12345